This part of the website is aimed at aiding doctors (especially GPs) to help facilitate and guide the decision to prescribe anticoagulation for patients with a new diagnosis of atrial fibrillation. Please click the start button to begin.
As non-valvular atrial fibrillation is not suspected or diagnosed, this tool isn't appropriate for this patient
When to use
The CHA2DS2-VASc score is one of several risk stratification schema that can help determine the 1 year risk of a TE event in a non-ant coagulated patient with non-valvular AF.
The CHA2DS2-VASc score, among other risk stratification schema, can be used to provide an idea of a patient’s risk for TE event.
Helps calculate the risk of stroke in an patient with Atrial fibrillation.
Congestive Heart Failure / or left ventricular failure?
If any features of Stroke/TIA/ TE?
Vascular Disease? (e.g. previous MI peripheral arterial disease or Aortic plaque)
The HAS-BLED score was developed as a practical risk score to estimate the 1-year risk for major bleeding in patients with atrial fibrillation.
Major bleeding defined as any bleeding requiring hospitalization, and/or causing a decrease in haemoglobin level > 2 g/L, and/or requiring blood transfusion that was not haemorrhagic stroke.
Consider using the HAS-BLED score as a tool to potentially guide the decision to start anticoagulation in patients with atrial fibrillation. Consider comparing the risk for major bleeding as calculated by the HAS-BLED score to the risk for thromboembolic events by the CHADS2 or CHA2DS2-VASc to determine if the benefit of anti-coagulation outweighs the risk.